Evidence map›Paper›PMID 35847500›Full record

ArticleActa pharmaceutica Sinica. B2022

A practical strategy to develop isoform-selective near-infrared fluorescent probes for human cytochrome P450 enzymes.

Lei Feng, Xiangge Tian, Dahong Yao, Zhenlong Yu, Xiaokui Huo, Zhenhao Tian, Jing Ning, Jingnan Cui, Tony D James, Xiaochi Ma

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Lei FengSecond Affiliated Hospital, Dalian Medical University, Dalian 116023, China.
Xiangge TianCollege of Pharmacy, the National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, Dalian Medical University, Dalian 116044, China.
Dahong YaoSchool of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen 518060, China.
Zhenlong YuCollege of Pharmacy, the National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, Dalian Medical University, Dalian 116044, China.
Xiaokui HuoSecond Affiliated Hospital, Dalian Medical University, Dalian 116023, China.
Zhenhao TianState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China.
Jing NingCollege of Pharmacy, the National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, Dalian Medical University, Dalian 116044, China.
Jingnan CuiState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China.
Tony D JamesDepartment of Chemistry, University of Bath, Bath BA2 7AY, UK.
Xiaochi MaSecond Affiliated Hospital, Dalian Medical University, Dalian 116023, China.
Dalian Medical University · CNDalian University of Technology · CNShenzhen Technology University · CNUniversity of Bath · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, the development of selective fluorescent probes toward targeted enzymes is still a great challenge, due to the existence of numerous isoenzymes that share similar catalytic capacity. Herein, a double-filtering strategy was established to effectively develop isoenzyme-specific fluorescent probe(s) for cytochrome P450 (CYP) which are key enzymes involving in metabolism of endogenous substances and drugs. In the first-stage of our filtering approach, near-infrared (NIR) fluorophores with alkoxyl group were prepared for the screening of CYP-activated fluorescent substrates using a CYPs-dependent incubation system. In the second stage of our filtering approach, these candidates were further screened using reverse protein-ligand docking to effectively determine CYP isoenzyme-specific probe(s). Using our double-filtering approach, probes

Indexed as

Biomarker analysisCYP, cytochrome P450Cytochrome P450DDI, drug–drug interactionsDNZ, danazolDrug–drug interactionsEnzyme activity bioimagingFluorescent probeFVT, fluvastatinHLM, human liver microsomeICT, intramolecular charge transferLC‒MS/MS, liquid chromatography‒tandem mass spectrometryMCN, miconazoleMD, molecular dynamicsMM-GBSA, binding free energy calculationNADPH, nicotinamide-adenine dinucleotide phosphateNIR, near-infraredPT, prothrombin timeRLX, raloxifeneRMSD, root-mean square deviationSCN, sulconazoleSPN, sulfaphenazoleWAR, warfarin

Identifiers

PMID35847500
PMCPMC9279627
OpenAlexW3216423051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.